iSpecimen Inc. (NASDAQ:ISPC) Short Interest Update

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 5,529,018 shares, an increase of 852.0% from the March 31st total of 580,752 shares. Currently, 21.2% of the shares of the company are short sold. Based on an average daily volume of 52,965,631 shares, the days-to-cover ratio is currently 0.1 days.

iSpecimen Stock Down 19.6%

ISPC traded down $0.03 on Friday, hitting $0.13. 27,448,865 shares of the company traded hands, compared to its average volume of 22,726,467. The company has a 50 day moving average of $0.20 and a 200-day moving average of $0.40. The stock has a market capitalization of $3.87 million, a PE ratio of -0.06 and a beta of 1.98. iSpecimen has a 12-month low of $0.10 and a 12-month high of $3.18.

iSpecimen (NASDAQ:ISPC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported ($0.74) EPS for the quarter. The company had revenue of $0.05 million for the quarter. iSpecimen had a negative net margin of 543.37% and a negative return on equity of 496.31%.

Institutional Trading of iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Virtu Financial LLC acquired a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned about 0.65% of iSpecimen as of its most recent SEC filing. Institutional investors own 13.62% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a research report on Tuesday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.